BioCentury | Mar 2, 2015
Company News

Diagnoplex, Novigenix deal

...Novigenix purchased Diagnoplex’s Colox , which is approved in Europe to detect colorectal cancer and pre-cancerous...
...test. Novigenix said it owns all of Diagnoplex’s assets and declined to provide financial details. Diagnoplex S.A....
BioCentury | Mar 10, 2014
Company News

Diagnoplex, Unilabs sales and marketing update

...Unilabs launched Diagnoplex's Colox colon cancer screening test in Switzerland. The test can detect colorectal cancer...
...will process the test at its diagnostic lab in Switzerland. Unilabs has rights to commercialize Diagnoplex's...
...Italy, Norway, Portugal, Russia, Spain, Sweden, Switzerland and the U.K. (see BioCentury, Sept. 30, 2013). Diagnoplex S.A....
BioCentury | Sep 30, 2013
Company News

Diagnoplex, Unilabs sales and marketing update

...1Q14. Unilabs declined to disclose financial terms, and Diagnoplex could not be reached for details. Diagnoplex S.A....
BioCentury | Jun 17, 2013
Financial News

Diagnoplex completes venture financing

Diagnoplex S.A. , Epalinges, Switzerland Business: Diagnostic Date completed: 6/7/13 Type: Venture financing Raised: CHF1.3 million ($1.4 million) Investors: Debiopharm Group ; NeoMed; Initiative Capital Romandie WIR Staff...
BioCentury | Jan 24, 2011
Financial News

Diagnoplex financial update

...Debiopharm Group . Diagno-plex raised CHF10 million ($10.3 million) in the round in December 2008. Diagnoplex S.A....
BioCentury | May 4, 2009
Product Development

From Micro to Macro

...cancer, in order to compete against other non-invasive tests in development that use different biomarkers. Diagnoplex...
...Colox mRNA-based test has shown 86% sensitivity and 95% specificity in early stage colon cancer. Diagnoplex...
...The program is in preclinical development. Companies and Institutions Mentioned Asuragen Inc. , Austin, Texas Diagnoplex...
BioCentury | Jun 23, 2008
Emerging Company Profile

Corporate Profile

Diagnoplex S.a.r.l. Epalinges, Switzerland Technology: Colox blood-based diagnostic test for colorectal cancer Disease focus: Cancer Clinical status: Pilot Founded: 2005 by Stavros Therianos, Jacques Essinger, Jean-Pierre Rosat, Novartis Venture Fund University collaborators: Swiss Institute for...
BioCentury | Jun 23, 2008
Emerging Company Profile

Diagnoplex: Simplifying colon screening

...the invasive nature of the test consistently leads to poor compliance among the at-risk population. Diagnoplex...
...years in the majority of cases. Rather than attempt to detect signals from the tumor, Diagnoplex’s...
...The company’s goal is to carve out a niche in the early cancer diagnostic space. Diagnoplex...
BioCentury | Jan 23, 2006
Finance

In and out at Novartis Venture

...M&A (Johnson & Johnson) 3/9/05 $230.0 XenoPort IPO 6/2/05 $201.9 Entries Company Focus Abriva Antibacterials Diagnoplex...
Items per page:
1 - 9 of 9
BioCentury | Mar 2, 2015
Company News

Diagnoplex, Novigenix deal

...Novigenix purchased Diagnoplex’s Colox , which is approved in Europe to detect colorectal cancer and pre-cancerous...
...test. Novigenix said it owns all of Diagnoplex’s assets and declined to provide financial details. Diagnoplex S.A....
BioCentury | Mar 10, 2014
Company News

Diagnoplex, Unilabs sales and marketing update

...Unilabs launched Diagnoplex's Colox colon cancer screening test in Switzerland. The test can detect colorectal cancer...
...will process the test at its diagnostic lab in Switzerland. Unilabs has rights to commercialize Diagnoplex's...
...Italy, Norway, Portugal, Russia, Spain, Sweden, Switzerland and the U.K. (see BioCentury, Sept. 30, 2013). Diagnoplex S.A....
BioCentury | Sep 30, 2013
Company News

Diagnoplex, Unilabs sales and marketing update

...1Q14. Unilabs declined to disclose financial terms, and Diagnoplex could not be reached for details. Diagnoplex S.A....
BioCentury | Jun 17, 2013
Financial News

Diagnoplex completes venture financing

Diagnoplex S.A. , Epalinges, Switzerland Business: Diagnostic Date completed: 6/7/13 Type: Venture financing Raised: CHF1.3 million ($1.4 million) Investors: Debiopharm Group ; NeoMed; Initiative Capital Romandie WIR Staff...
BioCentury | Jan 24, 2011
Financial News

Diagnoplex financial update

...Debiopharm Group . Diagno-plex raised CHF10 million ($10.3 million) in the round in December 2008. Diagnoplex S.A....
BioCentury | May 4, 2009
Product Development

From Micro to Macro

...cancer, in order to compete against other non-invasive tests in development that use different biomarkers. Diagnoplex...
...Colox mRNA-based test has shown 86% sensitivity and 95% specificity in early stage colon cancer. Diagnoplex...
...The program is in preclinical development. Companies and Institutions Mentioned Asuragen Inc. , Austin, Texas Diagnoplex...
BioCentury | Jun 23, 2008
Emerging Company Profile

Corporate Profile

Diagnoplex S.a.r.l. Epalinges, Switzerland Technology: Colox blood-based diagnostic test for colorectal cancer Disease focus: Cancer Clinical status: Pilot Founded: 2005 by Stavros Therianos, Jacques Essinger, Jean-Pierre Rosat, Novartis Venture Fund University collaborators: Swiss Institute for...
BioCentury | Jun 23, 2008
Emerging Company Profile

Diagnoplex: Simplifying colon screening

...the invasive nature of the test consistently leads to poor compliance among the at-risk population. Diagnoplex...
...years in the majority of cases. Rather than attempt to detect signals from the tumor, Diagnoplex’s...
...The company’s goal is to carve out a niche in the early cancer diagnostic space. Diagnoplex...
BioCentury | Jan 23, 2006
Finance

In and out at Novartis Venture

...M&A (Johnson & Johnson) 3/9/05 $230.0 XenoPort IPO 6/2/05 $201.9 Entries Company Focus Abriva Antibacterials Diagnoplex...
Items per page:
1 - 9 of 9